Efficacy and safety of reducing duration of infliximab infusion

Modern Rheumatology

Volumn 24, Issue 2, 2014, Pages 275-280

  Fukuyo, Shunsuke ^a   Saito, Kazuyoshi ^a   Yamaoka, Kunihiro ^a   Sawamukai, Norifumi ^a   Hirata, Shintaro ^a   Nawata, Masao ^a   Iwata, Shigeru ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

1 h; 30 min; Infliximab; Infusion reaction; Shortened infusion times

Indexed keywords

INFLIXIMAB;

ADULT; ARTICLE; DAS28; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG INFUSION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HUMAN; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84904973718     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2013.843747     Document Type: Article

References (14)

1. Klareskog L, Catrina A I, Paget S.Rheumatoid arthritis. Lancet. 2009 ; 373(9664) : 659-72.
2. StClair EW , van der Heijde DM , Smolen JS , Maini RN , Bathon JM , Emery P , et al. For the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004 ; 50(11) : 3432-43.
3. Lipsky PE , van der Heijde DM , StClair EW , Furst DE , Breedveld FC, Kalden JR, et al. For the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. NEngl J Med. 2000 ; 343(22) : 1594-602.
4. Yamanaka H , Tanaka Y , Sekiguchi N , Inoue E , Saito K , Kameda H , et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007 ; 17(1) : 28-32.
5. Tanaka Y , Takeuchi T , Inoue E , Saito K , Sekiguchi N , Sato E , et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: 1-year clinical and ragiographic outcomes (RECONFIRM-II). Mod Rheumatol. 2008 ; 18(2) : 146-52.
6. Takeuchi T , Yamanaka H , Inoue E , Nagasawa H , Nawata M , Ikari K , et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). Mod Rheumatol. 2008 ; 18(5) : 447-54.
7. Nawata M , Saito K , Nakayamada S , Tanaka Y.Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol. 2008; 18(5): 460-4.
8. Goekoop-Ruiterman YP , de Vries-Bouwstra JK , Allaart CF , van Zeben D , Kerstens PJ , Hazes JM , et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2008 ; 58(2 Suppl) : S126-35.
9. Tanaka Y , Takeuchi T , Mimori T , Saito K , Nawata M , Kameda H , et al. RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis. 2010 ; 69(7) : 1286-91.
10. Takeuchi T , Tatsuki Y , Nogami Y , Ishiguro N , Tanaka Y , Yamanaka H , et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008 ; 67(2) : 189-94
11. van Vollenhoven R F, Gullstrom E , Klareskog L.Feasibility of 1 hour infliximab infusions. Ann Rheum Dis. 2005 ; 64(4) : 654.
12. Buch M H, Bryer D , Lindsay S , Rees-Evans B , Fairclough A , Emery P.Shortening infusion times for infliximab administration. Rheumatology (Oxford). 2006; 45(4): 485-6.
13. Miyasaka N , Takeuchi T , Eguchi K.Proposed (corrected) Japanese guidelines for the use of infliximab for rheumatoid arthritis. Mod Rheumatol. 2005; 15(1): 4-8.
14. Ducourau E , Mulleman D , Goupille P.A ntibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther. 2011 ; 13(3) : 105.